Myelodysplastic Syndrome

Oncology·MeSH: Myelodysplastic Syndromes

Prevalence

13.0 / 100K

Incidence

4.6 / 100K/yr

59 drugs in development·34 companies·23 clinical trials

Drug Pipeline by Phase

Approved(6)

Drug	Company
azacitidine	Amneal Pharmaceuticals, Inc. (AMRX)
EVRENZO (爱瑞卓®) / roxadustat	KYNTRA BIO INC. (KYNB)
lenalidomide	Mylan II B.V. (MYL)
promacta	Novartis AG (NVS)
rytelo	GERON CORP (GERN)
Rytelo	Royalty Pharma plc (RPRX)

Phase 3(18)

Drug	Company
elritercept	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
elritercept	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
elritercept	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
elritercept (KER-050)	Keros Therapeutics, Inc. (KROS)
epoetin alfa	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
epoetin alfa	BRISTOL MYERS SQUIBB CO (BMY)
epoetin alfa	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Erythropoiesis-stimulating agents	BRISTOL MYERS SQUIBB CO (BMY)
JAK Inhibitor	Assertio Holdings, Inc. (ASRT)
Liposome-encapsulated Daunorubicin-Cytarabine	Jazz Pharmaceuticals plc (JAZZ)
luspatercept	CELGENE CORP /DE/ (CELG)
Luspatercept	BRISTOL MYERS SQUIBB CO (BMY)
pevonedistat	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
pevonedistat	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
roxadustat	KYNTRA BIO INC. (KYNB)
tak-226	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-226	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
velaglucerase alfa	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 2(17)

Drug	Company
abv-1702	ABVC BIOPHARMA, INC. (ABVC)
AG-946	AGIOS PHARMACEUTICALS, INC. (AGIO)
Busulfan	Assertio Holdings, Inc. (ASRT)
Elritercept	Merus N.V. (MRUS)
eltrombopag	Novartis AG (NVS)
Eltrombopag	Novartis AG (NVS)
Fludarabine	Assertio Holdings, Inc. (ASRT)
imetelstat	HWH International Inc. (HWH)
incb000928	Incyte Corp. (INCY)
incb024360	GH Research PLC (GHRS)
luspatercept	GH Research PLC (GHRS)
Melphalan	Assertio Holdings, Inc. (ASRT)
oxi4503	Oncotelic Therapeutics, Inc. (OTLC)
Tacrolimus	Assertio Holdings, Inc. (ASRT)
Tacrolimus	ENANTA PHARMACEUTICALS INC (ENTA)
TAK-226	Keros Therapeutics, Inc. (KROS)
Tebapivat	AGIOS PHARMACEUTICALS, INC. (AGIO)

Phase 1(7)

Drug	Company
ACLX-002	Arcellx, Inc. (ACLX)
cb-5339	CASI Pharmaceuticals, Inc (DE) (CASI)
CLN-049	Cullinan Therapeutics, Inc. (CGEM)
Imetelstat	Assertio Holdings, Inc. (ASRT)
lisaftoclax	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
sea-cd70	PFIZER INC (PFE)
sgr-2921	Schrodinger, Inc. (SDGR)

Preclinical(3)

Unknown(3)

Drug	Company
hypomethylating agents	BRISTOL MYERS SQUIBB CO (BMY)
reb blood cell transfusion	BRISTOL MYERS SQUIBB CO (BMY)
vonicog alfa	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 1/Phase 2(4)

Drug	Company
allogeneic umbilical cord mesenchymal stem cells	Curative Biotechnology Inc (CUBT)
nkx101	Nkarta, Inc. (NKTX)
r289	RIGEL PHARMACEUTICALS INC (RIGL)
r906289 mono	RIGEL PHARMACEUTICALS INC (RIGL)

Phase 2/Phase 3(1)

Drug	Company
Actimab-A	Actinium Pharmaceuticals, Inc. (ATNM)

BioSniper tracks 59 drugs in development for Myelodysplastic Syndrome across 34 companies.

There are 23 clinical trials targeting Myelodysplastic Syndrome tracked by BioSniper.

The estimated prevalence of Myelodysplastic Syndrome is approximately 13.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.